MicroStrategy
MSTR
Tesla
TSLA
Alphabet-A
GOOGL
Alphabet-C
GOOG
Coinbase
COIN
US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 6.340
- +0.150+2.42%
Close Dec 11 16:00 ET
- 6.340
- 0.0000.00%
Post 16:03 ET
346.33MMarket Cap9.61P/E (TTM)
6.360High6.084Low335.26KVolume6.220Open6.190Pre Close2.10MTurnover0.78%Turnover Ratio2.13P/E (Static)54.63MShares11.72052wk High1.05P/B273.91MFloat Cap5.19052wk Low--Dividend TTM43.20MShs Float31.910Historical High--Div YieldTTM4.46%Amplitude2.460Historical Low6.252Avg Price1Lot Size
About Voyager Therapeutics Company
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Company Profile
SymbolVYGR
Company NameVoyager Therapeutics
Listing DateNov 11, 2015
Issue Price14.00
Founded2013
CEODr. Alfred W. Sandrock, Jr,M.D.,PhD
MarketNASDAQ
Employees162
Fiscal Year Ends12-31
Address75 Hayden Avenue
CityLexington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02421
Phone1-857-259-5340
Company Executives
- Name
- Position
- Salary
- Dr. Alfred W. Sandrock, Jr,M.D.,PhD
- Director, President and Chief Executive Officer
- 3.17M
- Robin Swartz
- Chief Operating Officer
- 1.38M
- Jacquelyn Fahey Sandell, J.D.
- Chief Legal Officer
- 1.68M
- Toby Ferguson
- Chief Medical Officer
- --
- Dr. Todd Carter, PhD
- Chief Scientific Officer
- --
- Dr. Nathan Jorgensen, M.B.A.,PhD
- Chief Financial Officer and Principal Accounting Officer
- --
- Michael J. Higgins
- Chairman of the Board
- 281.28K
- Dr. Jude Onyia, PhD
- Director
- 452.32K
- Dr. Catherine J. Mackey, PhD
- Independent Director
- 250.78K
- Dr. George A. Scangos,PhD
- Independent Director
- 559.79K
- James A. Geraghty
- Independent Director
- 263.78K
- Nancy Vitale
- Independent Director
- 255.28K
- Dr. Glenn F. Pierce, M.D.,PhD
- Independent Director
- 248.78K
- Dr. Grace E. Colon, PhD
- Independent Director
- 432.23K
- Dr. Steven E. Hyman, M.D.
- Independent Director
- 255.78K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.